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In this study, we perform a full genome-wide association study (GWAS) to identify statistically 18 significantly associated single nucleotide polymorphisms (SNPs) with three red blood cell (RBC) 19 components and follow it with two independent PheWASs to examine associations between phenotypic 20 data (case-control status of diagnoses or disease), significant SNPs, and RBC component levels. We 21 first identified associations between the three RBC components: mean platelet volume (MPV), mean 22 corpuscular volume (MCV), and platelet counts (PC), and the genotypes of approximately 500,000 23
SNPs on the Illumina Infimum® DNA Human OmniExpress-24 BeadChip using a single cohort of 24 4,700 Northern Nevadans. Twenty-one SNPs in five major genomic regions were found to be 25 statistically significantly associated with MPV, two regions with MCV, and one region with PC, with 26
p<5x10
-8 . Twenty-nine SNPs and nine chromosomal regions were identified in 30 previous GWASs, 27 with effect sizes of similar magnitude and direction as found in our cohort. The two strongest 28 associations were SNP rs1354034 with MPV (p=2.4x10 -13 ) and rs855791 with MCV (p=5.2x10 -12 ).We 29 then examined possible associations between these significant SNPs and incidence of 1,488 phenotype 30 groups mapped from International Classification of Disease version 9 and 10 (ICD9 and ICD10) codes 31 collected in the extensive electronic health record (EHR) database associated with Healthy Nevada 32 Project consented participants. Further leveraging data collected in the EHR, we performed an 33 additional PheWAS to identify associations between continuous red blood cell (RBC) component 34 measures and incidence of specific diagnoses. The first PheWAS illuminated whether SNPs associated 35 with RBC components in our cohort were linked with other hematologic phenotypic diagnoses or 36 diagnoses of other nature. Although no SNPs from our GWAS were identified as strongly associated to 37 other phenotypic components, a number of associations were identified with p-values ranging between 38 1x10 -3 and 1x10 -4 with traits such as respiratory failure, sleep disorders, hypoglycemia, 39 hyperglyceridemia, GERD and IBS. The second PheWAS examined possible phenotypic predictors of 40
Introduction
61
The complete blood count (CBC) is a widely used medical diagnostic test that is a compilation of the 62 number, size, and composition of various components of the hematopoietic system. Abnormal CBC 63 measures may indicate illness or disease. Mean corpuscular volume (MCV), platelet count (PC), and 64
Results
115
Characteristics of cohort 116
We examined 4,700 genotyped individuals with at least one recorded RBC measure; 4,590 individuals 117 in the cohort had measures for all three components. 
GWAS of RBC components 129
Using the average measures of each individual's MPV, PC and MCV lab records, a standard GWAS 130 under the additive model with adjustments for gender, age and the first four principal components was 131 performed using PLINK 1.9. Genomic inflation coefficients (lambda) were computed for each cohort: 132 Figure S1 (A-C). As an example for the reader, we 139 include in the manuscript (Fig. 1) . We identified a strong 226 association in our cohort between platelet counts and thrombocytopenia and purpura (p<1x10 -30 ). 227
Associations with other hematologic phenotypes such as various anemias and pancytopenia also 228 reached significance (p<1x10 -8 ). Additionally, (morbid) obesity and cirrhosis were statistically 229 significantly associated with PC with p<1x10 -8 significance level. These three PheWAS results are 230 shown in Supplementary Fig S4(A-C) .
Discussion
234
In this study, we first performed three independent GWASs of 4,700 Healthy Nevada Project 235 participants with 500,000 genotypes against the RBC components: platelet count, mean platelet volume 236 and mean corpuscular volume. We followed these with two independent PheWASs for each component 237 Table 3 . 245 -09 ) in our cohort has not been linked to PC by other studies to the best of our knowledge. 291
Our strongest association (rs385893, p = 8.04×10 not necessarily support all-gender association between obesity and increased platelet counts, our 336 finding may reflect an association between the central obesity of metabolic syndrome and the 337 associated platelet activation of metabolic syndrome. However, the phenotype groups were not specific 338 enough to allow for specific differentiation between obesity types (See Supplementary Table S3) . 339 340 Thrombocytopenia is often observed in chronic liver disease and cirrhosis and platelet activation may 341 play a role in liver regeneration [76, 77] . Alcoholism is also associated with thrombocytopenia [78] . 342
However, evidence of an association between liver disease or alcoholism and platelet activation indices 343 is lacking. Moreover, evidence points to platelet function defects in chronic alcoholism [79] . Thus, the 344 negative effect of PC on cirrhosis and positive effect of MCV on cirrhosis, alcoholism, and alcohol-345 related disorders found in this study is intriguing and merits further confirmation and research. 346 347
Materials and Methods
348
The Renown EHR Database 349
The Renown Health EHR system was instated in 2007 on the EPIC system (EPIC System Corporation, 
IRB and Ethics Statement 362
The study was approved by our local Institutional Review Board (IRB, project 956068-12). Participants 363 in the Healthy Nevada Project consent to having genetic information associated with electronic health 364 information in a de-identified manner. Neither researchers nor participants have access to the complete 365 EHR data and cannot map participants to patient identifiers. These data are not incorporated into the 366 HER; rather, EHR and genetic data are linked in a separate environment via a unique identifier as 367 approved by the IRB. 368
Processing of EHR data 370
Most cohort participants had multiple RBC recordings across thirteen years; in these cases, the mean 371 age of each participant across those records was computed and later used as a Supplementary Fig S5(A-C) . 384
385
Genotyping and Quality Control 386
Genotyping was performed by 23andMe using the Illumina Infimum® DNA Human OmniExpress-24 387 BeadChip V4. This genotyping platform (Illumina, San Diego, CA) consists of approximately 570,000 388
SNPs. DNA extraction and genotyping were performed on saliva samples by the National Genetics 389
Institute (NG1), a CLIA licensed clinical laboratory and a subsidiary of the Laboratory Corporation of 390
America. 391 392
Raw genotype data were processed through a standard quality control process [46, 47, [80] [81] [82] . SNPs 393 with a minor allele frequency (MAF) less than 0.01 were removed. SNPS that were out of HWE (p-394 value < 1x10 -6 ) were also excluded. Any SNP with call rate less than 95% was removed; any individual 395 with a call rate less than 95% was also excluded from further study. Two pairs of participants were 396 excluded due to high IBS (Identical by State) in all three cohorts). Additionally, twelve people were 397 excluded due to high autosomal heterozygosity (FDR < components as covariates to correct for any bias generated by these variables. Standardized values of 413 all three components followed approximate normal distributions ( Supplementary Fig S5(A-C) The R package PheWAS This significance level is represented by a red line in Supplementary Fig S3(A-C) . 
GWAS Results 470
To reduce the possibility of a privacy breach, 23andMe requires that the statistics for only 10,000 SNPs 471 be made publicly available. This is the amount of data considered by 23andMe to be insufficient to 472 enable a re-identification attack. The statistical summary results of the top 10,000 SNPs for the 473 23andMe data are available here: https://www.dri.edu/grzymski2020. All column definitions are listed 474 in Table 5 . 475 
